Ethics and Drug & Biotechnology Policy
Publications
Journal Articles
2011
Doran E, Robertson J, Salkeld G, Henry D. Pharmaceutical Benefits Scheme Cost Sharing, Patient Cost Consciousness and Prescription Affordability. Australian Health Review. 2011; 35: 37-44.
Wang N, Lipworth W, Ritchie J, Williams K, Day R. Eliciting views of Australian Pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines. Internal Medicine Journal. 2011; 41(4): 314-20.
2009 – 2010
Carter SM, Samuel GN, Kerridge I, Day R, Ankeny RA, Jordens CFC, Komesaroff P. Beyond rhetoric in debates about the ethics of marketing prescription medicines to consumers: The importance of vulnerability in people, situations and relationships. American Journal of Bioethics Primary Research. 2010; 1(1): 11-21. From NHMRC 457497.
Chim L, Kelly P, Salkeld G, Stockler M. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? Pharmacoeconomics. 2010; 28 (6): 463-475.
Samuel G, Jordens CFC, Kerridge I. Direct-to-consumer personal genome testing: Ethical and regulatory issues that arise from wanting to “know” your DNA. Internal Medicine Journal. 2010; 40(3): 220–24.
Doran E and Robertson J Australia’s pharmaceutical cost sharing policy: reducing waste or affordability? Australian Health Review. 2009; 33(2):231-40.
Jordens CFC, Kerridge IH, Samuel G. Direct-to-consumer personal genome testing: The problem is not ignorance; it is market failure. American Journal of Bioethics. 2009; 9(6–7): 13-15.
2007 – 2008
Doran E and Henry DA. Disease Mongering – exploring the limits of legitimate marketing of medical products. Internal Medicine Journal. 2008; 38: 858–61.
Doran E, Henry DA. Australian Pharmaceutical Policy, Price Control and Drug Innovation in Australia. Journal of Public Health Policy. 2008; 29: 106–20.
Doran E, Henry DA, Faunce TA, Searles A Australian pharmaceutical policy and the idea of innovation. Journal of Australian Political Economy. 2008; 62: 39-61.
MacKenzie R, Chapman S, Salkeld G, Holding S. Media influence on Herceptin subsidization in Australia: application of the rule of rescue? J R Soc Med. 2008; 101(6): 305–12.
Mackenzie R, Chapman S, Stiven A, Holding S. The Rule of Rescue and media influence on health policy: Herceptin subsidization in Australia. J Roy Soc Med. 2008; 101:305-12. [Citations:10]
Moynihan R, Doran E, Henry D Disease mongering is now part of the global health debate. PLoS Med. 2008; 5(5): e106. doi:10.1371/journal. pmed.0050106.
Mackenzie FJ, Jordens CFC, Ankeny RA, McPhee J, Kerridge IH. DTCA under the radar: The need for more realistic drugs policy in Australia. Internal Medicine Journal. 2007; 37(4): 224-28.
2006
Doran E, Henry DA. Australian pharmaceutical policy: confused but tough on patients. Internal Medicine Journal. 2006; 36: 211-13.
Doran E, Kerridge I, McNeil P, Henry D. Empirical uncertainty and moral contest: A qualitative analysis of the relationship between medical specialists and the pharmaceutical industry. Social Science and Medicine. 2006; 62: 1510-19.